Today: 14 March 2026
Subscribe

Khadija Saeed

A dedicated markets reporter, she covers stocks, macroeconomics, and major business developments with a sharp eye for detail and accuracy.

Verizon stock slides after FCC loosens phone-unlocking rule as fraud fight takes center stage

Verizon stock slides after FCC loosens phone-unlocking rule as fraud fight takes center stage

Verizon shares fell 2.5% to $38.86 Tuesday after U.S. regulators scrapped a rule requiring the carrier to unlock phones 60 days after activation. The FCC’s order, effective immediately, follows Verizon’s claim that the rule fueled fraud involving nearly 785,000 devices last year. AT&T and T-Mobile also declined. Verizon separately disclosed changes to a $30 million executive stock award.
13 January 2026
·
Texas Instruments stock slips late in session as CPI hits tape and Jan. 27 earnings loom

Texas Instruments stock slips late in session as CPI hits tape and Jan. 27 earnings loom

Texas Instruments shares fell 0.5% to $188.12 Tuesday, lagging the broader chip sector as investors weighed new U.S. inflation data and awaited the company’s Jan. 27 earnings report. The iShares Semiconductor ETF rose 0.9%, while rivals Analog Devices and ON Semiconductor posted gains. U.S. consumer prices rose 0.3% in December, with core inflation up 2.6% year-over-year.
13 January 2026
·······
Verizon stock drops as FCC loosens phone unlocking rule and traders look to earnings next

Verizon stock drops as FCC loosens phone unlocking rule and traders look to earnings next

The FCC granted Verizon a waiver from its 60-day phone unlocking rule, allowing the carrier to follow broader industry standards. Verizon shares fell 2.4% to $38.89 Tuesday, underperforming peers after the decision. The company reported losing 784,703 devices to fraud in 2023. Verizon also amended a $30 million performance stock award for CEO Daniel H. Schulman.
13 January 2026
··
Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer shares fell 0.6% to $25.12 in Tuesday afternoon trading after CEO Albert Bourla discussed plans to accelerate obesity drug trials at the J.P. Morgan Healthcare Conference. Bourla said Pfizer aims to launch 10 Phase 3 trials for its Metsera portfolio by 2026 but does not expect revenue growth before 2029. Investors await the Feb. 3 earnings report for updates on the obesity pipeline and guidance.
13 January 2026
···
SoFi stock rises as Trump’s 10% credit-card cap idea shakes lenders — what investors watch next

SoFi stock rises as Trump’s 10% credit-card cap idea shakes lenders — what investors watch next

SoFi shares rose 1.1% to $26.89 Tuesday afternoon, outperforming a 0.4% drop in the S&P 500 as investors assessed Trump’s proposed 10% cap on credit card interest rates. The policy push has rattled banks and payments firms, who warn it could restrict credit. Wall Street analysts see legal hurdles but say fintech lenders like SoFi could benefit if banks tighten lending. Focus turns to SoFi’s Jan. 30 earnings.
13 January 2026
·
ServiceNow stock drops as Oppenheimer trims target — what to watch before earnings

ServiceNow stock drops as Oppenheimer trims target — what to watch before earnings

ServiceNow shares fell 3.3% to $137.95 Tuesday after Oppenheimer cut its price target to $200, citing sector concerns ahead of earnings. Goldman Sachs began coverage with a Buy rating and $205 target, while Citi maintained its Buy and placed the stock on a 30-day catalyst watch. The iShares Expanded Tech-Software ETF dropped 2%. Investors remain cautious after ServiceNow’s $7.75 billion Armis acquisition.
13 January 2026
··
AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie shares fell 0.1% to $219.83 Tuesday after announcing a three-year U.S. pricing deal tied to tariff exemptions. The company also signed a $650 million licensing agreement with China’s RemeGen for rights to an experimental cancer drug and bought a manufacturing site in Arizona. Management is set to speak at the J.P. Morgan Healthcare Conference on Jan. 14.
13 January 2026
··
Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam shares fell 0.1% to $370.39 Tuesday afternoon after the company projected 2026 net product revenue between $4.9 billion and $5.3 billion. Preliminary 2025 sales were disclosed at $2.987 billion. Analysts remained mostly positive but flagged possible weakness for Amvuttra next quarter. The update came as Alnylam outlined its new five-year strategy at the J.P. Morgan Healthcare Conference.
13 January 2026
··
Coca-Cola stock edges up after KO sets Feb. 10 earnings date; CAGNY appearance next

Coca-Cola stock edges up after KO sets Feb. 10 earnings date; CAGNY appearance next

Coca-Cola shares rose 0.5% to $70.83 Tuesday after the company set Feb. 10 for its Q4 and full-year earnings release and investor call. CEO-elect Henrique Braun and CFO John Murphy will speak at the CAGNY conference in Orlando on Feb. 17. Coke expects a $1 billion impairment charge in Q4 tied to its Africa bottling sale. PepsiCo shares gained 1.4% while the S&P 500 ETF slipped 0.4%.
13 January 2026
··
American Airlines stock drops 3.5% as Delta outlook and credit-card rate-cap worries hit airline shares

American Airlines stock drops 3.5% as Delta outlook and credit-card rate-cap worries hit airline shares

American Airlines shares fell 3.5% to $15.44 Tuesday, underperforming other major U.S. carriers as investors reacted to Delta’s profit forecast and concerns over a proposed 10% cap on credit-card interest rates. The cap could threaten airline loyalty program profits. American will report earnings Jan. 27, the same day the NTSB holds a hearing on a 2025 fatal crash involving one of its regional jets.
13 January 2026
·····
Amphenol stock rises as Barclays, Citi and Truist lift targets after CommScope deal closes

Amphenol stock rises as Barclays, Citi and Truist lift targets after CommScope deal closes

Amphenol shares rose 2.2% to $148.28 Tuesday, bucking a broader market decline after finalizing its $10.5 billion acquisition of CommScope’s CCS business. Analysts at Barclays, Citi, and Truist raised price targets, citing expected sales growth and stronger demand. The company projects CCS will add $4.1 billion in 2026 sales and $0.15 to EPS, excluding costs. Quarterly earnings are due Jan. 28.
13 January 2026
···
Wells Fargo stock slides ahead of earnings as credit-card rate cap talk rattles banks

Wells Fargo stock slides ahead of earnings as credit-card rate cap talk rattles banks

Wells Fargo shares fell 1.6% to $93.44 Tuesday, ahead of its fourth-quarter earnings release set for 7 a.m. ET Wednesday. The drop followed President Trump’s proposal for a 10% cap on credit card interest rates, which hit bank stocks. Trading volume reached 11.4 million shares. Investors are watching credit costs and margins amid policy uncertainty and fresh inflation data.
13 January 2026
··
Western Digital stock ticks up as WDC sets Jan. 29 earnings, putting AI storage demand in focus

Western Digital stock ticks up as WDC sets Jan. 29 earnings, putting AI storage demand in focus

Western Digital shares rose 1.6% to $215.57 on Tuesday, ahead of its fiscal Q2 results set for Jan. 29 after the market closes. The stock has swung sharply in recent sessions, fueled by AI-driven demand for storage and recent bullish comments from Nvidia’s CEO. Analysts expect quarterly EPS of $1.92 and revenue near $2.91 billion. Seagate also gained, while Micron fell 2.3%.
13 January 2026
····
Chevron stock climbs as oil jumps, but drones and a Jan. 17 deadline keep CVX traders on edge

Chevron stock climbs as oil jumps, but drones and a Jan. 17 deadline keep CVX traders on edge

Chevron shares rose 2.2% to $165.95 Tuesday after drones struck two Black Sea tankers, including one chartered by the company. Crude prices jumped as unrest in Iran fueled supply fears, with Brent up 2.5% to $65.44 a barrel. Chevron confirmed all crew are safe. War-risk insurance premiums for Black Sea shipping nearly doubled following the attacks.
13 January 2026
·····
1 … 319 320 321 322 323 … 704

Stock Market Today

  • Dogecoin's Journey: Millionaire-Maker Potential Examined
    March 14, 2026, 5:16 PM EDT. Dogecoin (DOGE) surged from $0.00026 in 2013 to near $0.096 today, turning a $10,000 early investment into $3.69 million. Fueled by celebrity endorsements and rising altcoin interest, Dogecoin's unique traits include unlimited supply and merge-mining with Litecoin, differing from capped tokens like Bitcoin. Its lack of smart contract support limits development, though the Dogechain Layer 2 solution aims to boost use. Critics cite its high supply and limited developer appeal as risks during potential market downturns. Regulatory progress, with spot ETFs pending SEC approval, could attract more investors. Yet, with a current market cap at $15 billion, Dogecoin would need an unprecedented surge to $14.5 trillion to replicate its initial returns, making a repeat millionaire-maker scenario highly improbable.
Go toTop